In a strategic partnership, QIAGEN and Myriad Genetics have jointly developed a distributable Homologous Recombination Deficiency (HRD) test for both global research and companion diagnostics applications. Leveraging QIAGEN’s groundbreaking QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary FDA-approved MyChoice CDx biomarkers, the next-generation sequencing-based HRD assay aims to support wider adoption and potentially expand the clinical indication for MyChoice CDx. This ambitious project builds upon the recent master collaboration agreement announced by the two companies.
Expanding HRD Testing Globally
The collaboration between QIAGEN and Myriad Genetics seeks to make the kit-based HRD test accessible on a global scale. By offering the test globally, they aim to facilitate research and the development of companion diagnostics in collaboration with pharmaceutical partners. This initiative will not only enhance the understanding and identification of HRD but also enable wider adoption of these diagnostics in potential clinical settings.
QIAseq xHYB Technology and MyChoice CDx Biomarkers
QIAGEN’s QIAseq xHYB technology has revolutionized next-generation sequencing by efficiently identifying genetic alterations known as structural variations (SVs). These SVs can drive cancer progression and are frequently associated with HRD. By utilizing this advanced technology, the HRD assay developed by QIAGEN and Myriad Genetics promises to improve the accuracy and reliability of HRD measurements.
In addition, Myriad’s proprietary FDA-approved MyChoice CDx biomarkers, which are widely recognized in the field, will be incorporated into the HRD assay. By combining the strengths of both QIAGEN and Myriad Genetics, this collaboration aims to develop a comprehensive and reliable HRD assay that can provide valuable insights for research and clinical diagnostics.
Significance for Pharmaceutical Partners and Clinical Indication Expansion
The availability of the kit-based HRD test for global distribution is envisioned to offer significant advantages to pharmaceutical partners. By leveraging this state-of-the-art HRD assay in their research and companion diagnostics development, pharmaceutical collaborators can enhance their understanding of HRD and potentially accelerate the discovery of novel therapeutic targets.
Furthermore, the collaboration between QIAGEN and Myriad Genetics holds the promise of expanding the clinical indication for MyChoice CDx. By providing improved HRD diagnostics, their efforts seek to enable physicians to more accurately identify patients who could potentially benefit from targeted treatments based on HRD status.
Conclusion
The partnership between QIAGEN and Myriad Genetics marks a significant milestone in the field of HRD testing. Through the development of a distributable HRD assay based on QIAGEN’s QIAseq xHYB technology and Myriad’s MyChoice CDx biomarkers, the collaboration aims to facilitate global research and companion diagnostics development. This initiative has the potential to enhance our understanding of HRD, help identify potential therapeutic targets, and, ultimately, improve patient outcomes.
Comments